Innovative AI Technology Deep 6 AI utilizes advanced artificial intelligence and natural language processing to significantly speed up patient matching for clinical trials, offering a compelling value proposition for healthcare organizations seeking efficient research solutions.

Strategic Acquisition The recent acquisition by Tempus, expanding access to over 30 million patients and 750 provider locations, provides a growth opportunity to target large healthcare networks and pharmaceutical companies looking to leverage extensive data and infrastructure.

Expanding Collaborations Partnerships with firms like Graticule and Bio Optronics demonstrate Open to collaboration with data providers and healthcare tech companies, creating potential avenues for joint offerings and integrated solutions to target research institutions.

Funding Momentum With a strong funding history of 27 million dollars and a revenue range of 10 to 25 million dollars, Deep 6 AI is well-positioned to invest in sales outreach and scale its client base within the clinical research and life sciences sectors.

Market Positioning As a mid-sized player competing with larger firms like IQVIA and Parexel, Deep 6 AI offers innovative, AI-driven clinical trial solutions, making it an attractive option for organizations seeking cutting-edge technology with agile deployment capabilities.